Health care stocks were easing Monday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%.
The iShares Biotechnology ETF (IBB) rose 0.1%.
In corporate news, PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease. PTC shares jumped 18% and Novartis was down 0.9%.
Senti Biosciences (SNTI) shares soared 469%. The company said Monday that two of three acute myeloid leukemia patients treated with its Senti-202 investigational cell therapy for blood cancers achieved complete remission in a phase 1 trial.
Gelteq (GELS) shares surged 28% after it said Monday its largest client in the US, Healthy Extracts, has increased its order of the company's collagen and Mynus sugar blocker gels by 50%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。